Quarterly report [Sections 13 or 15(d)]

SEGMENT REPORTING

v3.25.3
SEGMENT REPORTING
9 Months Ended
Sep. 30, 2025
SEGMENT REPORTING  
SEGMENT REPORTING

NOTE 3 – SEGMENT REPORTING

 

Operating segments comprised of the components of an entity in which separate information is available for evaluation by the Company’s CODM, or group of decision makers, in determining how to allocate resources in evaluating performance. The Company consists of a single reporting segment: life science. The life science segment is comprised of the Company’s development of therapeutics that target lipid-signaling modulation pathways, including the ECS, a network of receptors and neurotransmitters that form a biochemical communication system throughout the body. The Company’s CODM is its chief executive officer.

 

The accounting policies of the life science segment are as described in the summary of significant accounting policies. The CODM evaluates the performance of the life science segment based on the Company’s net loss as reported on the income statement as consolidated net loss. The Company’s segment assets are reported on the balance sheet as its total consolidated assets.

 

The Company has not generated any revenue since its inception and expects to continue to incur losses into the foreseeable future as it continues to conduct research and development related activities through all stages of product development and clinical trials and subsequently seek approval from the respective regulatory authorities. The Company’s CODM utilizes cash forecast models to determine the Company’s investment in the life sciences segment. These models are reviewed regularly to monitor the Company’s operating results and performance and compared to the Company’s cash-based forecasts.

 

 

 

Three Months Ended

 

 

 

September 30,

 

 

 

2025

 

 

2024

 

General and administrative

 

 

 

 

 

 

Employee and director compensation

 

$ 229

 

 

$ 228

 

Stock-based compensation

 

 

240

 

 

 

135

 

Professional fees

 

 

1,013

 

 

 

181

 

Other general and administrative (a)

 

 

332

 

 

 

326

 

Total general and administrative

 

$ 1,814

 

 

$ 870

 

 

 

 

Nine Months Ended

 

 

 

September 30,

 

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

General and administrative

 

 

 

 

 

 

Employee and director compensation

 

$ 700

 

 

$ 702

 

Stock-based compensation

 

 

440

 

 

 

408

 

Professional fees

 

 

2,050

 

 

 

734

 

Other general and administrative (a)

 

 

898

 

 

 

935

 

Total general and administrative

 

$ 4,088

 

 

$ 2,779

 

 

 

 

Three Months Ended

 

 

 

September 30,

 

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

Research and development

 

 

 

 

 

 

Employee compensation

 

$ 267

 

 

$ 157

 

Stock-based compensation

 

 

188

 

 

 

74

 

Professional fees

 

 

262

 

 

 

1,137

 

Other research and development (b)

 

 

558

 

 

 

(1,043 )

Total research and development

 

$ 1,275

 

 

$ 325

 

 

 

Nine Months Ended

 

 

 

September 30,

 

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

Research and development

 

 

 

 

 

 

Employee compensation

 

$ 743

 

 

$ 625

 

Stock-based compensation

 

 

331

 

 

 

209

 

Professional fees

 

 

3,466

 

 

 

3,483

 

Other research and development (b)

 

 

(10 )

 

 

(800 )

Total research and development

 

$ 4,530

 

 

$ 3,517

 

 

(a)

Consists of investor relations, travel and other office expenses.

(b)

Consists of supplies and other items used in research and development activities.